16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
18:17 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Clearside reports Phase II DME data for CLS-TA

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in...
21:35 , May 31, 2018 |  BC Extra  |  Clinical News

Clearside falls on Phase II DME data

Clearside Biomedical Inc. (NASDAQ:CLSD) lost $4.68 (32%) to $9.86 on Thursday after reporting that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular...
17:51 , May 3, 2018 |  BC Innovations  |  Translation in Brief

Hydrogels on demand

Alivio Therapeutics is using a hydrogel platform to develop controlled-release therapies for inflammatory diseases that respond to flare-ups as they occur. The approach, described in an April Nature Communications study, could avoid systemic toxicities associated...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate that...
22:00 , Mar 22, 2018 |  BC Innovations  |  Strategy

Janssen’s virtual discovery

In the latest example of how AI can accelerate drug discovery, Janssen has shown it can use machine learning to create virtual drug screens that outperform conventional assays. The most promising application may be in...
17:18 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Clearside macular edema program headed for submission

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA met the primary endpoint in the Phase III PEACHTREE trial to treat macular edema associated with non-infectious uveitis. Clearside plans to submit an NDA to FDA in...
21:24 , Mar 5, 2018 |  BC Extra  |  Clinical News

Clearside macular edema program headed for submission

Clearside Biomedical Inc. (NASDAQ:CLSD) added $2.51 (32%) to $10.33 on Monday after reporting that suprachoroidal CLS-TA met the primary endpoint in the Phase III PEACHTREE trial to treat macular edema associated with non-infectious uveitis. Clearside...
15:23 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Oric raises $50M series C

Cancer company Oric Pharmaceuticals Inc. (South San Francisco, Calif.) said on Feb. 21 it raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS...
21:51 , Feb 21, 2018 |  BC Extra  |  Financial News

Oric raises $50M series C

Oric Pharmaceuticals Inc. (South San Francisco, Calif.) raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS Investment. Existing investors, including The Column Group,...